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ABSTRACT 
A multi-marker approach is increasingly considered in diagnosis of prostate cancer to 
minimize the number of unnecessary biopsies [1]. Centrifugo-pneumatic flow control is often the 
method of choice for multiplexing such assays [2]. However, the number of assays that can be 
parallelized on such a dissolvable-film (DF) based system is limited by the substantial spread of the 
burst frequencies [2] owing to manufacturing tolerances. In this work we substantially enhance the 
definition of actuation frequencies by 75% using a novel design to enable the automation of multi-
step / multi-reagent Lab-on-a-Disc (LoaD) platform. We demonstrate a multi-marker prostate cancer 
immunoassay panel. 
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INTRODUCTION 
Centrifugal microfluidic systems for decentralized testing at the point-of-care employ rotationally 
induced sample preparation and flow control which can be implemented on a rugged and cost-effici-
ent instrument [1]. We recently introduced a new, rotationally controlled flow technology based on 
disc-incorporated DF membranes that offers decisive benefits [2]. However, the substantial spread of 
the burst frequencies which is linked to unavoidable manufacturing tolerances remains a limiting fac-
tor [2]. In this work we substantially enhance the definition of actuation frequencies by 75% (from an 
average of ±7.5 Hz down to ±1.8 Hz) using a novel design to enable the comprehensive automation of 
multi-step / multi-reagent immunoassay panels on the LoaD platform. As a pilot application, we 
implement the sample handling required for the detection of two prostate cancer markers (fPSA and 
Her2 ECD) with two different Enzyme-Linked Immuno-Sorbent Assays (ELISAs). 
 
EXPERIMENTAL 
The entire sample preparation of three parallel assays from whole blood is solely orchestrated by 
changes in the spin speed of the LoaD cartridge featuring specifically designed DF valves (Fig. 1). 
Figure 2 shows the novel design for the DF valving which employs: a by-pass chamber ensuring a 
controlled rise of liquid before reaching the DF valve; a trigger lip placed at the end of this bypass 
chamber that directly opens to the recess of the DF tab; a separately connected pneumatic chamber 
the volume of which sets the burst frequency of the valve (in accordance with the Boyles law); and a 
peripherally placed DF valve that allows immediate dissolution of the DF upon the entry of the first 
liquid. 
 
RESULTS AND DISCUSSION 
The new valve design (Fig. 2) considerably improves the reliability, thus permitting a higher 
integration density for increasing the number of bioassays that can be parallelized on a single disc 
cartridge as in Figure 1. Figure 3 shows the results for fPSA and Her2 detection from buffer on the 
LoaD for a run time of 53 minutes. 
 
CONCLUSION 
While the emphasis of this work is on the fluidic automation of the multiplexed assay, we are 
already able to demonstrate the detection of Her2 and fPSA within and near the clinical ranges of 15 - 
75 ng ml
-1
 and 4 ng ml
-1
, respectively. The sensitivity may be improved factors by addressing adverse 
factors such as denaturation of the proteins on the disc surface.  
 Figure 1: Illustration of a LoaD system for the 
detection of a prostate cancer panel composed of 
fPSA and Her2 markers from whole blood. 
 
 
Figure 2: Actuation of centrifugo-pneumatically 
triggered DF valves based in the overflow lip 
mechanism. All distances are measured from the 
axis of rotation. (A) Initially, the liquid (red) is 
held back in the inlet reservoir. (B) At elevated spin rates, the centrifugally induced hydrostatic pressure com-
presses the enclosed gas so the liquid front advances past the trigger lip to open the DF. 
 
Figure 3: 
Signal-to-
noise ab-
sorbance 
results for 
immunoas-
says on the 
LoaD to de-
tect fPSA 
and Her2 
biomarkers 
marker 
from buffer. 
Error bars 
indicate standard deviation from at least three measurements. The clinical ranges for the markers are: HER2 
levels ranging from 15 ng ml-1 to as high as 75 ng ml-1 diagnosed as cancer. PSA level > 4.0 ng ml-1 is consid-
ered as a cut-off value for recommending biopsy [3]. 
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